Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Beta Bionics recently brought its iLet bionic pancreas to market in 2023 and completed an IPO to become a publicly-traded ...

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

Zerodha’s Nithin Kamath sparks debate on Ozempic, Mounjaro & their game-changing impact on obesity, addiction & industries. Is India ready for this shift?

Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to ...

GLP-1 weight loss drugs cost CT’s Medicaid program $85 million in FY 2024, 35% of annual Medicaid pharmaceutical budget ...

A recent study released by researchers from Pohang University of Science and Technology (POSTECH) opens the door for more effective diabetes research and treatment. The new approach leverages ...

In the quest for health and wellness, Australians are constantly on the lookout for effective weight loss strategies. For ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...